David Hallal, Director at iTeos Therapeutics, Inc. (ITOS), sold 58,059 shares at $20.39 ($1.2M) on 2022-06-08, disclosed to the SEC on 2022-06-10.
Open-market sale of $1.2M ITOS by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $19.86 | 10,577 | $210K | 17.9% |
| 2 | $19.86 | 10,577 | $210K | 17.9% |
| 3 | $20.39 | 5,968 | $122K | 10.4% |
| 4 | $20.39 | 11,899 | $243K | 20.7% |
| 5 | $20.39 | 11,899 | $243K | 20.7% |
| 6 | $20.39 | 5,968 |
| $122K |
| 10.4% |
| 7 | $19.51 | 1,171 | $23K | 2.0% |
| Total | $20.18 avg | 58,059 | $1.2M | 100% |
| Filing → |
| ITOS | SELL | 2025-06-06 | $2.3M | — | Filing → |
| ALVR | SELL | 2022-10-21 | $5.1M | — | Filing → |
| ALVR | SELL | 2022-09-30 | $2.9M | — | Filing → |